Presentation made by Drs. Charles Driscoll and Ms. Angela Taylor at the live webinar hosted by AlzPossible on the 29th of May, 2014. See recording at http://www.alzpossible.org/wordpress-3.1.4/wordpress/webinars-2/dementia-with-lewy-bodies/
Lewy body dementia (LBD), also known as dementia with Lewy bodies, is the second most common type of progressive dementia after Alzheimer's disease. LBD is caused by the accumulation of abnormal protein deposits called Lewy bodies in brain cells. These Lewy bodies can affect thinking, movement, behavior, and mood. A definitive diagnosis of LBD can only be made through a brain autopsy, but clinical diagnosis is based on a set of characteristic symptoms that include fluctuating cognition, visual hallucinations, and parkinsonism. The Lewy Body Dementia Association provides resources and support for those affected by LBD.
Dementia with Lewy bodies (DLB) is diagnosed based on progressive cognitive decline along with core clinical features such as fluctuating cognition, visual hallucinations, REM sleep behavior disorder, and spontaneous parkinsonism. Biomarkers like reduced dopamine transporter uptake and abnormal MIBG scans provide supportive evidence. DLB is managed through a multidisciplinary approach including accurate diagnosis, symptom identification and intervention, education of caregivers, and a team-based care plan. Treatment focuses on cholinesterase inhibitors for cognitive and neuropsychiatric symptoms, though antiparkinsonian drugs require caution due to increased risk of psychosis.
Dementia with Lewy Bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer's disease. It is clinically defined by dementia, hallucinations, fluctuations in alertness, and parkinsonism. Autopsy shows Lewy Bodies in the neocortex and brainstem in 15-36% of demented cases. DLB involves a core set of features including fluctuating cognition, visual hallucinations, and spontaneous motor features of parkinsonism. It is differentiated from other dementias by its symptom profile and neuropathology.
This document discusses Lewy body dementia, including its clinical features such as visual hallucinations and parkinsonism. It describes two types of Lewy body dementia: diffuse Lewy body disease, which presents at an early age with widespread Lewy body formation and rapid progression, and Lewy body variant of Alzheimer's disease, which presents later in life with mild parkinsonism and global cognitive impairment. The diagnosis, medications used to treat it such as cholinesterase inhibitors and antiparkinson drugs, and behavioral management strategies are also outlined.
Dementia can sometimes be caused by reversible conditions. This document discusses several potential reversible causes of dementia, including thyroid disorders, vitamin deficiencies, infections, and side effects of medications like steroids. It provides details on specific disorders and how treatment of the underlying condition may resolve cognitive and behavioral symptoms. Reversible dementias are estimated to account for 18% of cases under 65 but only 5% of those over 65. While treatment can sometimes improve symptoms, complete reversion of cognitive impairment is unclear for certain conditions like Cushing's syndrome.
This document provides an overview of frontotemporal dementia (FTD) including its causes, clinical presentation, diagnosis, and management options. It discusses that FTD is caused by protein misfolding and accumulation in the brain. There are three main clinical variants - behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Diagnosis involves ruling out other causes and may include brain imaging. Treatment focuses on managing symptoms but medications have limited effectiveness. Caregiver burden can be high due to patient behaviors, so support groups are recommended.
This document discusses reversible causes of dementia and delirium. It begins by defining major neurocognitive disorder and reversible dementias. Common reversible causes of dementia include central nervous system infections, normal pressure hydrocephalus, nutritional deficiencies, drugs, endocrine disorders, depression, and sleep apnea. Delirium is then discussed, including risk factors, pathophysiology, clinical subtypes, DSM-5 criteria, assessment scales, differential diagnosis, course, prevention, and management. Reversible dementias are estimated to account for 8-40% of dementia cases. Early diagnosis and treatment of the underlying cause can improve cognitive functioning.
Lewy body dementia was first discovered in the early 1900s and involves protein deposits in the brain that affect brain function and cause Parkinson's-like symptoms. It can be difficult to diagnose due to similarities with Parkinson's disease, but indicators include progressive cognitive decline, fluctuating cognition and attention, visual hallucinations, and REM sleep behavior disorder. Treatments include medications to slow cognitive decline and manage Parkinsonism symptoms, as well as non-pharmacological therapies and counseling. An accurate diagnosis allows for better symptom management and quality of life.
Lewy body dementia (LBD), also known as dementia with Lewy bodies, is the second most common type of progressive dementia after Alzheimer's disease. LBD is caused by the accumulation of abnormal protein deposits called Lewy bodies in brain cells. These Lewy bodies can affect thinking, movement, behavior, and mood. A definitive diagnosis of LBD can only be made through a brain autopsy, but clinical diagnosis is based on a set of characteristic symptoms that include fluctuating cognition, visual hallucinations, and parkinsonism. The Lewy Body Dementia Association provides resources and support for those affected by LBD.
Dementia with Lewy bodies (DLB) is diagnosed based on progressive cognitive decline along with core clinical features such as fluctuating cognition, visual hallucinations, REM sleep behavior disorder, and spontaneous parkinsonism. Biomarkers like reduced dopamine transporter uptake and abnormal MIBG scans provide supportive evidence. DLB is managed through a multidisciplinary approach including accurate diagnosis, symptom identification and intervention, education of caregivers, and a team-based care plan. Treatment focuses on cholinesterase inhibitors for cognitive and neuropsychiatric symptoms, though antiparkinsonian drugs require caution due to increased risk of psychosis.
Dementia with Lewy Bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer's disease. It is clinically defined by dementia, hallucinations, fluctuations in alertness, and parkinsonism. Autopsy shows Lewy Bodies in the neocortex and brainstem in 15-36% of demented cases. DLB involves a core set of features including fluctuating cognition, visual hallucinations, and spontaneous motor features of parkinsonism. It is differentiated from other dementias by its symptom profile and neuropathology.
This document discusses Lewy body dementia, including its clinical features such as visual hallucinations and parkinsonism. It describes two types of Lewy body dementia: diffuse Lewy body disease, which presents at an early age with widespread Lewy body formation and rapid progression, and Lewy body variant of Alzheimer's disease, which presents later in life with mild parkinsonism and global cognitive impairment. The diagnosis, medications used to treat it such as cholinesterase inhibitors and antiparkinson drugs, and behavioral management strategies are also outlined.
Dementia can sometimes be caused by reversible conditions. This document discusses several potential reversible causes of dementia, including thyroid disorders, vitamin deficiencies, infections, and side effects of medications like steroids. It provides details on specific disorders and how treatment of the underlying condition may resolve cognitive and behavioral symptoms. Reversible dementias are estimated to account for 18% of cases under 65 but only 5% of those over 65. While treatment can sometimes improve symptoms, complete reversion of cognitive impairment is unclear for certain conditions like Cushing's syndrome.
This document provides an overview of frontotemporal dementia (FTD) including its causes, clinical presentation, diagnosis, and management options. It discusses that FTD is caused by protein misfolding and accumulation in the brain. There are three main clinical variants - behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Diagnosis involves ruling out other causes and may include brain imaging. Treatment focuses on managing symptoms but medications have limited effectiveness. Caregiver burden can be high due to patient behaviors, so support groups are recommended.
This document discusses reversible causes of dementia and delirium. It begins by defining major neurocognitive disorder and reversible dementias. Common reversible causes of dementia include central nervous system infections, normal pressure hydrocephalus, nutritional deficiencies, drugs, endocrine disorders, depression, and sleep apnea. Delirium is then discussed, including risk factors, pathophysiology, clinical subtypes, DSM-5 criteria, assessment scales, differential diagnosis, course, prevention, and management. Reversible dementias are estimated to account for 8-40% of dementia cases. Early diagnosis and treatment of the underlying cause can improve cognitive functioning.
Lewy body dementia was first discovered in the early 1900s and involves protein deposits in the brain that affect brain function and cause Parkinson's-like symptoms. It can be difficult to diagnose due to similarities with Parkinson's disease, but indicators include progressive cognitive decline, fluctuating cognition and attention, visual hallucinations, and REM sleep behavior disorder. Treatments include medications to slow cognitive decline and manage Parkinsonism symptoms, as well as non-pharmacological therapies and counseling. An accurate diagnosis allows for better symptom management and quality of life.
Frontotemporal dementia (FTD) is the second most common early-onset dementia. There are several variants of FTD including behavioral variant FTD and primary progressive aphasias like semantic dementia and progressive nonfluent aphasia. Genetic causes include mutations in MAPT, GRN, and C9ORF72 genes. Neuroimaging shows characteristic patterns of frontal and temporal lobe atrophy depending on the variant. Biomarkers like increased blood GFAP levels may help with diagnosis. Currently, there are no approved disease-modifying treatments, but some medications may help treat symptoms. Research focuses on new targets like gene therapy to potentially slow progression in the future.
The document provides an overview of the approach to dementia. It discusses the diagnostic criteria for dementia, epidemiology, etiology including neurodegenerative, vascular, neurological and other causes. It describes cortical vs subcortical dementia and reversible vs irreversible dementias. The document also provides details on how to diagnose a case of dementia including history, examination, investigations and differential diagnosis. Specific subtypes like Alzheimer's disease, vascular dementia, frontotemporal dementia, Lewy body dementia, Parkinson's disease, normal pressure hydrocephalus and CJD are also discussed.
This document provides information about dementia, including:
1. Dementia is characterized by progressive deterioration of intellect, behavior, and personality due to diffuse brain disease, especially affecting the cortex and hippocampus. Memory impairment is required for diagnosis.
2. Symptoms include memory loss, abnormal behavior, intellectual decline, mood changes, and difficulty with daily tasks. Insight is initially retained but lost over time.
3. Causes of dementia include Alzheimer's disease (60% of cases), cerebrovascular disease, neurodegenerative diseases, infections, head injuries, and tumors. Dementia must be distinguished from delirium and depression.
This document provides an overview of the treatment of dementia. It discusses the definition and classification of dementia, as well as the staging and types of dementia. It then describes the pathophysiology and management of dementia, including both pharmacologic and non-pharmacologic approaches. Regarding pharmacologic management, it outlines three broad categories of treatment: symptomatic treatment of memory disturbance, disease-modifying treatments, and symptomatic treatment of behavioral disturbances. Specific drugs discussed in detail include cholinesterase inhibitors such as donepezil, rivastigmine, and tacrine.
Vascular dementia is caused by problems in the supply of blood to the brain, often due to conditions like strokes or mini-strokes. It is characterized by stepwise cognitive decline following vascular events and symptoms that overlap with Alzheimer's disease, though it often occurs at a younger age. Risk factors include age, history of strokes, high blood pressure, diabetes, smoking, and atrial fibrillation. Treatment focuses on controlling vascular risk factors and symptoms.
This document outlines an approach to diagnosing and evaluating dementia. It discusses the subtypes of mild cognitive impairment and dementia, the importance of a detailed patient history and neurological exam, and diagnostic criteria. Investigations may include cognitive testing, brain imaging, and lab tests to identify reversible causes or distinguish between dementia subtypes like Alzheimer's disease or Lewy body dementia. Follow up is important to monitor progression. The take home message is that dementia causes significant impairment, so a thorough history and early diagnosis are crucial.
Neuropsychiatric manifestations in neurological disorderswebzforu
The document discusses neuropsychiatric manifestations that can occur in neurological disorders. It summarizes that cerebral white matter is connected to other brain regions and plays an important role in behavior. White matter disorders can cause issues like cognitive loss, dementia, mood disorders, and psychosis. Specific white matter diseases are described along with their neurobehavioral impacts. Neuropsychiatric symptoms seen in neurological conditions are outlined. Finally, common neurological diseases associated with psychiatric symptoms like depression, anxiety, psychosis, mania, and aggression are listed.
Treatment resistant schizophrenia is defined as lack of satisfactory improvement despite trials of two antipsychotics for adequate duration and dose. Around 20-30% of schizophrenia patients are considered treatment resistant. Clozapine is currently the treatment of choice for such patients, though combination and augmentation strategies with other agents have limited evidence. Definitive treatment guidelines recommend establishing treatment resistance before trials of clozapine or other strategies for treatment resistant schizophrenia.
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
This document summarizes the use of medications to treat dementia. It discusses cholinesterase inhibitors like donepezil, rivastigmine, and galantamine, which are first-line treatments for mild-to-moderate Alzheimer's disease. Memantine is recommended for moderate-to-severe cases. These drugs aim to boost acetylcholine and inhibit glutamate to slow cognitive decline. SSRIs are preferred over anticholinergics for depression. Atypical antipsychotics may help psychosis but carry stroke risk. Lifestyle changes and alternative therapies can also help manage symptoms like agitation, depression, and disinhibition.
This document provides an overview of dementia, including its definition, diagnosis, causes, and approach to evaluation and management. It defines dementia as acquired cognitive impairment that interferes with daily life. The diagnostic criteria from the DSM-V are outlined. Common causes of dementia like Alzheimer's disease, vascular dementia, and Lewy body dementia are reviewed. The document discusses taking a history, performing a physical and neurological exam, cognitive testing, and medical investigations to diagnose the underlying cause of dementia.
This presentation looks at generalised periodic epileptiform discharges and the various disorders like Creutzfeldt Jacob disease (CJD), SSPE and metabolic encephalopathies in which it is seen. SIRPID is also discussed. Triphasic waves are described. Radermacker complexes in SSPE are described.
1) Cognitive decline is a normal part of aging, but dementia is characterized by multiple cognitive deficits severe enough to interfere with daily life. The DSM-V criteria distinguish between mild and major neurocognitive disorders.
2) Mild cognitive impairment (MCI) represents an intermediate stage between normal aging and dementia, with greater cognitive decline than normal but preserved independence. Amnestic MCI is highly predictive of Alzheimer's disease.
3) Biomarkers like MRI, CSF analysis, PET imaging, and genetics can help predict conversion from MCI to dementia and distinguish Alzheimer's disease from other causes. Biomarkers show changes decades before symptoms appear in preclinical Alzheimer's disease.
The document provides an overview of dementia and Alzheimer's disease. It defines dementia and its main components. It describes the most common types of dementia, including Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and others. It covers the pathology, risk factors, stages, diagnosis, differential diagnosis, and workup for Alzheimer's disease.
1. The document discusses various variants of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It describes clinical features and electrodiagnostic patterns of AIDP subtypes including AMAN and AMSAN as well as regional and atypical variants of GBS like Miller Fisher Syndrome. 2. Rare autoimmune nodopathies caused by antibodies targeting nodes of Ranvier are described. Clinical features associated with antibodies to contactin-1, neurofascin 155, neurofascin isoforms and contactin-associated protein 1 are summarized. 3. Diagnostic criteria and variants of CIDP
The document discusses psychiatric manifestations that commonly occur in dementia such as Alzheimer's disease and dementia with Lewy bodies. It describes symptoms such as apathy, anxiety, agitation, and depression. Psychotic symptoms like hallucinations and delusions are also addressed. The prevalence of various neuropsychiatric symptoms is provided for mild cognitive impairment and different stages of Alzheimer's disease and dementia with Lewy bodies. Factors that influence the risk of developing certain psychiatric symptoms are also outlined.
Alzheimer's disease is a progressive brain disorder that destroys memory and cognitive skills. Dr. Alois Alzheimer first described it in 1906 after examining a woman with dementia. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms but do not stop the underlying disease process. Researchers are exploring therapies targeting amyloid and tau proteins as well as other mechanisms to find a cure.
Corticobasal degeneration is a rare progressive neurodegenerative disease typically presenting in patients' 60s with asymmetric parkinsonism and cognitive dysfunction. It is characterized by focal cortical atrophy and tau-positive lesions in the cortex and basal ganglia. Diagnosis relies on clinical features and exclusion of other conditions, while neuropathological examination confirms the diagnosis. Currently there is no cure, and treatment focuses on managing symptoms through a multimodality approach, though available therapies have limited effectiveness.
This document discusses autoimmune encephalitis, which occurs due to antibodies against neuronal cell proteins or synaptic receptors. It can comprise 5-10% of encephalitis cases. The most common type is anti-NMDAR encephalitis, which targets the NMDA receptor. It most often affects females under 18 and follows a predictable clinical course with psychiatric, neurological, and decreased consciousness symptoms. Diagnosis involves identifying antibodies in CSF or serum and MRI/EEG may show nonspecific abnormalities. Treatment involves immunotherapy like steroids, IVIG, plasma exchange, and rituximab. Outcomes range from full recovery to relapse or residual deficits.
This document discusses mental health issues in people with intellectual disabilities. It covers several common psychiatric conditions seen in this population including schizophrenia, depression, mania, and dementia. Key points include:
- People with intellectual disabilities are at high risk for mental illness, though symptoms can be overlooked.
- Schizophrenia symptoms like hallucinations and delusions may present differently than in the general population.
- Depression and mania can also affect people with intellectual disabilities but may be expressed differently.
- Dementia is also more common in some populations like those with Down syndrome.
- Caregivers play an important role in monitoring for changes that could indicate mental illness.
Frontotemporal dementia (FTD) is the second most common early-onset dementia. There are several variants of FTD including behavioral variant FTD and primary progressive aphasias like semantic dementia and progressive nonfluent aphasia. Genetic causes include mutations in MAPT, GRN, and C9ORF72 genes. Neuroimaging shows characteristic patterns of frontal and temporal lobe atrophy depending on the variant. Biomarkers like increased blood GFAP levels may help with diagnosis. Currently, there are no approved disease-modifying treatments, but some medications may help treat symptoms. Research focuses on new targets like gene therapy to potentially slow progression in the future.
The document provides an overview of the approach to dementia. It discusses the diagnostic criteria for dementia, epidemiology, etiology including neurodegenerative, vascular, neurological and other causes. It describes cortical vs subcortical dementia and reversible vs irreversible dementias. The document also provides details on how to diagnose a case of dementia including history, examination, investigations and differential diagnosis. Specific subtypes like Alzheimer's disease, vascular dementia, frontotemporal dementia, Lewy body dementia, Parkinson's disease, normal pressure hydrocephalus and CJD are also discussed.
This document provides information about dementia, including:
1. Dementia is characterized by progressive deterioration of intellect, behavior, and personality due to diffuse brain disease, especially affecting the cortex and hippocampus. Memory impairment is required for diagnosis.
2. Symptoms include memory loss, abnormal behavior, intellectual decline, mood changes, and difficulty with daily tasks. Insight is initially retained but lost over time.
3. Causes of dementia include Alzheimer's disease (60% of cases), cerebrovascular disease, neurodegenerative diseases, infections, head injuries, and tumors. Dementia must be distinguished from delirium and depression.
This document provides an overview of the treatment of dementia. It discusses the definition and classification of dementia, as well as the staging and types of dementia. It then describes the pathophysiology and management of dementia, including both pharmacologic and non-pharmacologic approaches. Regarding pharmacologic management, it outlines three broad categories of treatment: symptomatic treatment of memory disturbance, disease-modifying treatments, and symptomatic treatment of behavioral disturbances. Specific drugs discussed in detail include cholinesterase inhibitors such as donepezil, rivastigmine, and tacrine.
Vascular dementia is caused by problems in the supply of blood to the brain, often due to conditions like strokes or mini-strokes. It is characterized by stepwise cognitive decline following vascular events and symptoms that overlap with Alzheimer's disease, though it often occurs at a younger age. Risk factors include age, history of strokes, high blood pressure, diabetes, smoking, and atrial fibrillation. Treatment focuses on controlling vascular risk factors and symptoms.
This document outlines an approach to diagnosing and evaluating dementia. It discusses the subtypes of mild cognitive impairment and dementia, the importance of a detailed patient history and neurological exam, and diagnostic criteria. Investigations may include cognitive testing, brain imaging, and lab tests to identify reversible causes or distinguish between dementia subtypes like Alzheimer's disease or Lewy body dementia. Follow up is important to monitor progression. The take home message is that dementia causes significant impairment, so a thorough history and early diagnosis are crucial.
Neuropsychiatric manifestations in neurological disorderswebzforu
The document discusses neuropsychiatric manifestations that can occur in neurological disorders. It summarizes that cerebral white matter is connected to other brain regions and plays an important role in behavior. White matter disorders can cause issues like cognitive loss, dementia, mood disorders, and psychosis. Specific white matter diseases are described along with their neurobehavioral impacts. Neuropsychiatric symptoms seen in neurological conditions are outlined. Finally, common neurological diseases associated with psychiatric symptoms like depression, anxiety, psychosis, mania, and aggression are listed.
Treatment resistant schizophrenia is defined as lack of satisfactory improvement despite trials of two antipsychotics for adequate duration and dose. Around 20-30% of schizophrenia patients are considered treatment resistant. Clozapine is currently the treatment of choice for such patients, though combination and augmentation strategies with other agents have limited evidence. Definitive treatment guidelines recommend establishing treatment resistance before trials of clozapine or other strategies for treatment resistant schizophrenia.
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
This document summarizes the use of medications to treat dementia. It discusses cholinesterase inhibitors like donepezil, rivastigmine, and galantamine, which are first-line treatments for mild-to-moderate Alzheimer's disease. Memantine is recommended for moderate-to-severe cases. These drugs aim to boost acetylcholine and inhibit glutamate to slow cognitive decline. SSRIs are preferred over anticholinergics for depression. Atypical antipsychotics may help psychosis but carry stroke risk. Lifestyle changes and alternative therapies can also help manage symptoms like agitation, depression, and disinhibition.
This document provides an overview of dementia, including its definition, diagnosis, causes, and approach to evaluation and management. It defines dementia as acquired cognitive impairment that interferes with daily life. The diagnostic criteria from the DSM-V are outlined. Common causes of dementia like Alzheimer's disease, vascular dementia, and Lewy body dementia are reviewed. The document discusses taking a history, performing a physical and neurological exam, cognitive testing, and medical investigations to diagnose the underlying cause of dementia.
This presentation looks at generalised periodic epileptiform discharges and the various disorders like Creutzfeldt Jacob disease (CJD), SSPE and metabolic encephalopathies in which it is seen. SIRPID is also discussed. Triphasic waves are described. Radermacker complexes in SSPE are described.
1) Cognitive decline is a normal part of aging, but dementia is characterized by multiple cognitive deficits severe enough to interfere with daily life. The DSM-V criteria distinguish between mild and major neurocognitive disorders.
2) Mild cognitive impairment (MCI) represents an intermediate stage between normal aging and dementia, with greater cognitive decline than normal but preserved independence. Amnestic MCI is highly predictive of Alzheimer's disease.
3) Biomarkers like MRI, CSF analysis, PET imaging, and genetics can help predict conversion from MCI to dementia and distinguish Alzheimer's disease from other causes. Biomarkers show changes decades before symptoms appear in preclinical Alzheimer's disease.
The document provides an overview of dementia and Alzheimer's disease. It defines dementia and its main components. It describes the most common types of dementia, including Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and others. It covers the pathology, risk factors, stages, diagnosis, differential diagnosis, and workup for Alzheimer's disease.
1. The document discusses various variants of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It describes clinical features and electrodiagnostic patterns of AIDP subtypes including AMAN and AMSAN as well as regional and atypical variants of GBS like Miller Fisher Syndrome. 2. Rare autoimmune nodopathies caused by antibodies targeting nodes of Ranvier are described. Clinical features associated with antibodies to contactin-1, neurofascin 155, neurofascin isoforms and contactin-associated protein 1 are summarized. 3. Diagnostic criteria and variants of CIDP
The document discusses psychiatric manifestations that commonly occur in dementia such as Alzheimer's disease and dementia with Lewy bodies. It describes symptoms such as apathy, anxiety, agitation, and depression. Psychotic symptoms like hallucinations and delusions are also addressed. The prevalence of various neuropsychiatric symptoms is provided for mild cognitive impairment and different stages of Alzheimer's disease and dementia with Lewy bodies. Factors that influence the risk of developing certain psychiatric symptoms are also outlined.
Alzheimer's disease is a progressive brain disorder that destroys memory and cognitive skills. Dr. Alois Alzheimer first described it in 1906 after examining a woman with dementia. The disease is characterized by beta-amyloid plaques and neurofibrillary tangles in the brain. Current treatments aim to improve symptoms but do not stop the underlying disease process. Researchers are exploring therapies targeting amyloid and tau proteins as well as other mechanisms to find a cure.
Corticobasal degeneration is a rare progressive neurodegenerative disease typically presenting in patients' 60s with asymmetric parkinsonism and cognitive dysfunction. It is characterized by focal cortical atrophy and tau-positive lesions in the cortex and basal ganglia. Diagnosis relies on clinical features and exclusion of other conditions, while neuropathological examination confirms the diagnosis. Currently there is no cure, and treatment focuses on managing symptoms through a multimodality approach, though available therapies have limited effectiveness.
This document discusses autoimmune encephalitis, which occurs due to antibodies against neuronal cell proteins or synaptic receptors. It can comprise 5-10% of encephalitis cases. The most common type is anti-NMDAR encephalitis, which targets the NMDA receptor. It most often affects females under 18 and follows a predictable clinical course with psychiatric, neurological, and decreased consciousness symptoms. Diagnosis involves identifying antibodies in CSF or serum and MRI/EEG may show nonspecific abnormalities. Treatment involves immunotherapy like steroids, IVIG, plasma exchange, and rituximab. Outcomes range from full recovery to relapse or residual deficits.
This document discusses mental health issues in people with intellectual disabilities. It covers several common psychiatric conditions seen in this population including schizophrenia, depression, mania, and dementia. Key points include:
- People with intellectual disabilities are at high risk for mental illness, though symptoms can be overlooked.
- Schizophrenia symptoms like hallucinations and delusions may present differently than in the general population.
- Depression and mania can also affect people with intellectual disabilities but may be expressed differently.
- Dementia is also more common in some populations like those with Down syndrome.
- Caregivers play an important role in monitoring for changes that could indicate mental illness.
OCD is an anxiety disorder characterized by recurrent unwanted thoughts (obsessions) and repetitive behaviors (compulsions). It affects about 3.3 million American adults and is equally common in males and females. Effective treatment involves a combination of medication like SSRIs and exposure therapy, where patients are exposed to feared situations without engaging in compulsions. With proper treatment including medication and therapy, most OCD patients see a reduction in symptoms and can function well.
This document provides information about dementia to help general practices become more dementia-friendly. It defines dementia, describes the most common types (Alzheimer's disease, vascular dementia, dementia with Lewy bodies), and their symptoms. Case studies illustrate how dementia can affect behavior and communication. Models are used to explain memory loss. The document discusses visual problems people with dementia experience and tips for effective communication. It provides resources for diagnosis, support for carers, and ways practices can help such as understanding patients' experiences.
Sure, let's calculate the cumulative GPA based on the provided SGPA for each semester. I'll assume that each semester has the same number of credit hours for simplicity. If the credit hours vary, you would need to provide that information as well.
Here's the calculation:
\[ \text{Cumulative GPA} = \frac{(3.78 \times \text{Credits}) + (3.75 \times \text{Credits}) + (3.56 \times \text{Credits}) + (3.5 \times \text{Credits}) + (3.61 \times \text{Credits}) + (3.57 \times \text{Credits})}{6 \times \text{Credits}} \]
If the credit hours for each semester are the same, you can simplify this to:
\[ \text{Cumulative GPA} = \frac{3.78 + 3.75 + 3.56 + 3.5 + 3.61 + 3.57}{6} \]
Now, you can calculate the value:
\[ \text{Cumulative GPA} = \frac{21.77}{6} \approx 3.6283 \]
So, your cumulative GPA based on the provided SGPA for the first six semesters is approximately \(3.63\) on a scale of 4.0.Certainly! I can help you calculate your GPA based on the SGPA (Semester Grade Point Average) of your first 6 semesters. To calculate the cumulative GPA, you need to use the following formula:
\[ \text{Cumulative GPA} = \frac{\text{Sum of (SGPA * Credits)}}{\text{Total Credits}} \]
Here, SGPA is the Semester Grade Point Average, and Credits represent the credit hours for each course. You sum up the products of SGPA and Credits for all your semesters and then divide by the total number of credits.
If you provide me with the SGPA and the corresponding credits for each semester, I can assist you in calculating your cumulative GPA.Certainly! I can help you calculate your GPA based on the SGPA (Semester Grade Point Average) of your first 6 semesters. To calculate the cumulative GPA, you need to use the following formula:
\[ \text{Cumulative GPA} = \frac{\text{Sum of (SGPA * Credits)}}{\text{Total Credits}} \]
Here, SGPA is the Semester Grade Point Average, and Credits represent the credit hours for each course. You sum up the products of SGPA and Credits for all your semesters and then divide by the total number of credits.
If you provide me with the SGPA and the corresponding credits for each semester, I can assist you in calculating your cumulative GPA.Certainly! I can help you calculate your GPA based on the SGPA (Semester Grade Point Average) of your first 6 semesters. To calculate the cumulative GPA, you need to use the following formula:
\[ \text{Cumulative GPA} = \frac{\text{Sum of (SGPA * Credits)}}{\text{Total Credits}} \]
Here, SGPA is the Semester Grade Point Average, and Credits represent the credit hours for each course. You sum up the products of SGPA and Credits for all your semesters and then divide by the total number of credits.
If you provide me with the SGPA and the corresponding credits for each semester, I can assist you in calculating your cumulative GPA. Certainly! I can help you calculate your GPA based on the SGPA (Semester Grade Point Average) of your first 6formesters.
This document discusses psychotic disorders and their pharmacotherapy. It defines psychotic disorders as illnesses that make it difficult to think clearly and behave appropriately. It describes several types of psychosis including schizophrenia, schizoaffective disorder, delusional disorder, and dissociative disorders. Symptoms are outlined along with possible causes such as genetics and drug abuse. Diagnosis involves medical history, exams, and scans. Treatment involves antipsychotic drugs which work to reduce disturbed behaviors associated with delusions and hallucinations. Atypical antipsychotics are most commonly used now due to their better efficacy and safety profile.
The document discusses various mental disorders and assessments, noting that the "Big Three" mental disorders are dementia, depression, and delirium. It provides true/false questions about the characteristics and treatments of conditions like Alzheimer's disease, Parkinson's disease, anxiety disorders, and schizophrenia. The document also addresses factors to consider in assessing mental health across the adult lifespan and among different ethnic groups.
This document discusses neurocognitive disorders including delirium, major neurocognitive disorders such as dementia and amnestic syndrome, mild neurocognitive disorder, epilepsy, and traumatic brain injury. It provides details on the diagnostic criteria, clinical features, epidemiology, treatment, and prognosis of these conditions. Case studies are also presented to illustrate delirium and complex partial seizures.
The psychological approaches and examples are outlined and evaluated. The treatments and therapies for each approach are given and also evaluated. Based on the Third Edition for Psychology AS 'The Complete Companion Student Book' by Mike Cardwell and Cara Flanagan for AQA 'A'
This document provides information about cognitive disorders such as dementia and delirium. It defines key terms, describes symptoms, causes, diagnostic procedures and nursing care approaches. The main points covered are: dementia involves progressive cognitive decline while delirium has rapid onset and fluctuating symptoms. Common types of dementia include Alzheimer's disease. Symptoms of delirium include impaired attention and cognition. Causes can be medical conditions, substances or multiple factors. Assessment involves tests of cognition, brain imaging and ruling out physical causes. Nursing care prioritizes safety, communication, reducing confusion and promoting well-being and family support.
Major depressive disorder and childhood bipolar disorder can present with a variety of symptoms beyond just depressed mood. Assessment of these conditions requires evaluating potential comorbidities, social contexts, relationships, and risk factors. Treatment may involve antidepressant medication, psychotherapy like CBT, and monitoring for several months. Bipolar disorder in particular can be hard to diagnose in children due to overlapping symptoms with other conditions.
This document provides information about dementia to help general practitioners increase their understanding and ability to support patients and families affected by dementia. It defines different types of dementia, describes common symptoms, discusses the impact on brain regions, and provides case studies and models to illustrate experiences. It also offers guidance on communication strategies, visual issues patients may experience, and resources to help practices become more dementia-friendly.
This document summarizes common childhood psychiatric disorders presented by doctors in Bangladesh. It discusses:
1. The increasing prevalence of psychiatric disorders in children worldwide and in Bangladesh based on epidemiological studies.
2. Common disorders seen in Bangladeshi children including anxiety disorders, ADHD, autism spectrum disorders, somatic symptom disorder, and elimination disorders.
3. The causes of rising psychiatric disorders in children such as modern life stresses, technology overuse, and family changes. Treatment approaches including behavioral therapy and pharmacotherapy are mentioned.
Dylan was born prematurely at 6 months due to his mother's pre-eclampsia and high maternal age. He exhibited developmental delays and low cognitive functioning. He was misdiagnosed initially and struggled socially and academically. By age 17 he was accurately diagnosed with mild intellectual disability stemming from his preterm birth and lack of early stimulation exacerbated by his mother's post-birth depression. His condition was managed through specialized education and support from family.
Caroline, a 32-year-old nurse, had been working long hours and night shifts during the COVID-19 pandemic. Due to budget issues, her salary was often delayed, adding to her stress. Her husband noticed changes in her behavior like waking up early to do rituals and not doing household chores. At work, she spoke very fast, took extra shifts, and told patients she could treat them due to her connection with God. She was diagnosed with bipolar I disorder based on her symptoms of manic episodes including inflated self-esteem, decreased need for sleep, and rapid speech.
This document discusses an age-friendly primary care partnership between Fontenelle and UNMC's Geriatrics Workforce Enhancement Program. It receives funding from HRSA and focuses on the 4 M's in primary care: Mentation, which includes delirium, dementia, and depression. Dementia is discussed in more detail, covering etiology, evaluation involving history, physical exam, and labs/imaging, diagnostic criteria for Alzheimer's disease, and treatment options. Delirium is also summarized, including assessment using the Confusion Assessment Method.
This document provides information about Alzheimer's disease and dementia. Some key points:
- Alzheimer's disease is the most common form of dementia and causes nerve cell death and brain tissue loss. It is progressive, irreversible, and fatal.
- The first case was identified in 1901 by Alois Alzheimer. The term "Alzheimer's disease" was coined in 1910.
- Risk factors include genetic mutations, age, and lifestyle. The disease develops due to plaques, tangles, and neuronal loss in the brain.
- Symptoms start with mild cognitive decline and progress to severe cognitive and physical impairment. It affects memory, thinking, behavior, and ability to perform daily tasks.
- Over 5 million
Bipolar disorder is characterized by alternating periods of mania and depression. It can be disabling but treatable. Catherine Zeta Jones has openly discussed her diagnosis of bipolar II disorder in 2011 after experiencing manic and depressive episodes. Treatment involves mood stabilizing medications, therapy, and lifestyle changes like maintaining routines. While frustrating for caregivers, bipolar disorder is a chronic illness with relapses common due to noncompliance with treatment.
This document defines dementia and delirium, differentiates between the two, and provides assessment and management tips for delirium. It notes that delirium is acute with sudden onset while dementia has slow onset and decline. Key points are that delirium is underrecognized, has poor outcomes if left untreated, and can be prevented and managed by addressing potential triggers and maintaining hydration, mobility, and nutrition. Assessment tools like CAM and 4AT can help identify delirium which requires prompt treatment of the underlying cause.
Robin Murray commentary during the SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia is not a single disease but rather two different syndromes according to the DSM-5 and ICD-10 diagnostic criteria, with only 70% of patients meeting criteria for both. This raises questions about what to call patients who meet one but not the other and how useful the term "schizophrenia" is given the lack of biological markers and different interpretations by psychiatrists. Looking at dimensions of psychosis symptoms, predominant causes, and severity/persistence may provide more helpful information to patients and their outcomes than the term schizophrenia.
Eske Derks commentary - SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia patients are qualitatively different from their healthy siblings and controls based on genetic studies. While there is some genetic overlap between schizophrenia, psychosis, and general mental health risk, distinct genetic factors for schizophrenia have also been found. Specifically, over 200 genetic risk factors for schizophrenia have been identified. Based on these genetic findings, the presenter concludes that schizophrenia is not simply an extreme on a normal distribution of traits and replacing it with a psychosis spectrum disorder would be premature.
Jim van Os presentation during SRF live webinar "Is Schizophrenia Dead Yet?"wef
This document discusses the debate around schizophrenia diagnoses and proposes an alternative psychosis spectrum syndrome approach. It summarizes that the debate is about clinical diagnosis, not research criteria. It also notes that around 3.5% of people experience some form of psychosis, but the current system publishes overwhelmingly on only one category, schizophrenia. The document advocates for recognizing a spectrum approach and dimensional personal diagnoses within a categorical psychosis spectrum to better reflect individuals' experiences and needs.
Rene Kahn commentary during SRF Live Webinar: "Is Schizophrenia Dead Yet?wef
Schizophrenia and bipolar disorder are distinct conditions with little genetic overlap and different risk factors. Schizophrenia is primarily a cognitive disorder, not defined by psychosis, as cognitive decline precedes psychotic episodes. While some wish to deny the poor prognosis of schizophrenia, studies show the disorder leads to reduced life expectancy, high suicide and unemployment rates, and long-term functional impairment for most patients.
NIMH i PSC Assays for the Drug Pipeline - Panchisionwef
Dr David Panchision's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
Schizophrenia Research Forum Live Webinar - June 28, 2017 - Rusty Gage wef
1) The document describes a study using induced pluripotent stem cells (iPSCs) derived from bipolar disorder (BD) patients to model the disease in vitro.
2) Hippocampal dentate gyrus-like neurons were differentiated from iPSCs and showed hyper-excitability at both the molecular and functional levels in BD-derived neurons.
3) Treatment with lithium rescued the hyper-excitability phenotype in neurons derived from lithium-responsive BD patients but not lithium non-responsive patients, suggesting patient-specific responses.
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
Kristen Brennand presentation at the live webinar of June 28, 2017 hosted by the Schizophrenia Research Forum (http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models)
STRATEGIES FOR COMMUNICATION AND SENSITIVITY FOR PERSONS EXPERIENCING DEMENTI...wef
This document summarizes a workshop on strategies for communicating with persons experiencing dementia. It discusses how communication is impacted at different stages of dementia from early to late stage. In early stage, word retrieval becomes difficult. In middle stage, language abilities further decline making conversation challenging. In late stage, communication is limited but sensory stimulation through touch, sound, and smell can still connect a person. The workshop provides guidance on adapting approaches to best communicate with someone based on their stage of dementia.
Translating from Animal Models to Human Schizophrenia - Insights into Pathoph...wef
Presentation made by Dr. Tony Grace at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Presentation made by Dr. Oliver Howes at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Topography and functional significance of the dopaminesgic dysfunction in sch...wef
Presentation made by Dr. Anissa Abi-Dargham at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
SRF Webinar - What It Will Take to Make Coordinated Specialty Care Available ...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
SRF Webinar: Beyond DUP - Addressing Disengagement in Community-based Early I...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
This document provides an overview of memory loss, dementia, and Alzheimer's disease. It defines key terms, describes symptoms at different stages of dementia, and discusses a person-centered approach to care. The main points are:
1) Dementia is not a specific disease but a general term for symptoms caused by various brain disorders, while Alzheimer's disease is the most common cause of progressive dementia.
2) Early stage dementia symptoms include memory loss, impaired judgment, and difficulty completing tasks, while middle and late stage symptoms involve greater impairment and dependence on others for care.
3) A person-centered approach focuses on maintaining an individual's dignity, independence, and identity through techniques like validation, respect, and personalized
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
HEAR approach to behavior management Live webinar Feb 1 2017wef
Slides presented at the HEAR Approach to Behavior Management live webinar of February 1, 2017, featuring presentations from Dr. Andrew Heck and Carol Garby.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Lewy body dementia webinar final
1. Dementia with
Lewy Bodies:
Charles E. Driscoll, MD, FAAFP
Geriatrician; Emeritus Professor of Family Medicine
University of Virginia
Lynchburg, VA
Angela Taylor
Director of Programs
Lewy Body Dementia Association
Lilburn, GA
Clarity
Emerging from
Confusion
2. Poll
• Do you work with or know someone who has Lewy
Body Dementia?
• Yes
• No
3. Abbreviations
• DLB – Dementia with Lewy Bodies
• LB – Lewy Body
• LBD – Lewy Body Dementia
• MMSE – Mini Mental State Examination
• PDD – Parkinson’s Disease Dementia
• REM – Rapid Eye Movement
4. Learning Objectives
Recognize it!
Know how it differs from other
dementias
Understand LB is a spectrum of
diseases
Treatment and Management issues
Family Care and Support Issues
5. The Slow Road of
Discovery
Dr. Friedrich Lewy
identifies protein
1912
Hallmarks
described in 1996
Added to
International
Classification of
Diseases in 2005
Today, recognized
as the second
most common
form of
progressive
dementia
6. Micrograph of brain cells containing a Lewy
body which is an abnormal aggregation of
protein
Lewy bodies can be more
easily detected using special
antibody staining against the
α-synuclein protein
Tau protein and tangles
within a neuron cell
8. Case Scenario - Hal
• Hal, a veteran, retired from his work as an auto
mechanic at age 68.
• His boss had noticed a number of Hal’s repairs needed
some review and “tweaking”.
• Hal’s wife noticed he is more forgetful, becomes
confused when following directions, and has some
difficulties finding “the right word” in conversation.
• Health is good with BP 134/84 and his only medications
are a baby aspirin and a multi-vitamin daily.
• Smokes 1ppd.
9. Poll…
• Select the elements necessary to make a diagnosis of
dementia
• Demonstrated memory loss
• Hallucinations
• Interference with day to day function
• Delusions
• 2 or more cognitive areas involved
10. Does He Have Dementia?
Necessary
Elements for a
diagnosis:
Memory loss:
subjective
and
objective
Trouble in a
second cognitive
domain
Language, Executive
Function, Motor Skills,
Social Skills, Visual-
Spatial, Learning,
Attention
Interference with
day-to-day
function
11. Poll – open ended question
• Name 3 symptoms that might suggest a diagnosis of DLB?
Please use your Questions tab to enter three such symptoms
(separated by commas)
12. Another Look at Our
Patient, Hal
Having been diagnosed with early dementia, Hal is seen
again in 6 months. His wife notes some new problems:
• He is sleeping and barely rousable for long periods
during the day
• He has become suspicious when his wife leaves the
house, and thinks she is trying to sell their home
• Sleep at night is disrupted by nightmares with “hitting at
something in the dream”
• A “sedative” was prescribed for the sleep problem, but it
had paradoxical effects, raising his anxiety and
restlessness
13. What Clues Can Suggest
DLB?
Fluctuation – good days and bad days
REM sleep behavior disorder
Difficulty with complex mental activities
Day-time sleepiness
Medication sensitivity – tranquilizers and neuroleptics
Motor dysfunction
Vivid hallucinations/Delusions
Autonomic dysfunction
Abnormal brain imaging
14. REM Sleep Behavior
Disorder
• Acting out dreams
• Sometimes injured by falling out of bed
• Sometimes injure sleep mate
• May appear years before DLB diagnosis
• Red flag symptom
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
15. Difficulty with Complex
Mental Activities
• Executive function severely impaired
• Visuospatial dysfunction
• Decline in attention
• Memory often relatively spared in the early
stage
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
16. Cognitive Fluctuation
• Most difficult to define and identify
• Fluctuation of MMSE scores by >5
points up & down over 6-month period
• Family members say:
• “appears drowsy, but awake”, “looks dazed”
• “not aware of what is going on”
• “can be fine one day and confused the next”
• Minutes, hours or days between periods
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
17. Hallucinations and
Delusions
Hallucinations
– usually
visual
• more frequent in patients with poor
eyesight
• not unpleasant, but very real
Delusions –
usually
misidentificati
on type
• someone is present in the room
• phantom boarder delusion
• people are stealing things
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
18. Motor Dysfunction
• Fine motor skills are lost
• Rigidity
• Parkinson symptoms
• Tremor
• Slowness of movement (bradykinesia)
• Shuffling gait
• Loss of balance
• Falls
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
19. Autonomic Dysfunction
REM sleep behavior disorder
Difficulty with complex mental activities
Fluctuation – good days and bad days
Day-time sleepiness
Medication sensitivity
Vivid hallucinations/Delusions
Motor dysfunction
Autonomic dysfunction
Abnormal brain imaging
20. Putting it All Together
LEWY
BODY
DEMENTIA
Visual hallucinations and/or sensitivity
to neuroleptics
Acting out dreams
(REM Sleep Behavior Disorder)
and/or other sleep disturbances
Motor dysfunction
(may look like Parkinson’s)
Autonomic dysfunction
Cognitive dysfunction
(may look like AD)
Fluctuating levels of attention
(may mimic delirium)
21. Taxonomy is somewhat arbitrary
• No major clinical differences, both, DLB and PDD are LBD
• ICD-9 codes are the same – 331.82
Is it DLB, PDD, or LBD?
12 months
PDD
DLB
BY CONSENSUS:
IF
22. Poll
• What is one medication that should always be
avoided in DLB?
• Aricept
• Valium
• Seroquel
• Haldol
• Prozac
23. Treating Behavior LBD Disturbances
Always
evaluate for
physical
problem.
• Is it delirium?
Avoid or
reduce
medications.
•Benzodiazepines,
bladder
Avoid
traditional
antipsychotics
•Hallucinations and psychotic behaviors appear to be related
to cholinergic deficits.
•Try:
• Donepezil, Rivastigmine, and Galantamine – a long term “fix.”
• If urgent, try Quetiapine or Clozapine.
• Note “black box” warnings to family.
Use for
shortest
duration
•Educate
patient/family
24. Research Needed: Racial and
Socioeconomic Disparities
Parkinson’s Disease
African
Americans
Whites
Disease prevalence may be higher X
Seek care earlier at specialty clinic X
Greater disability X
Greater disease severity X
More likely to be prescribed
dopaminergic medications,
especially newer ones
X
More likely to be prescribed
antipsychotics X
25. Importance of an
Early Diagnosis
• These patients respond differently to:
• Neuroleptic medications
• Anti-cholinesterase inhibitors
• Parkinson’s medications
• Different progression than Alzheimer’s
• Shorter prognosis
• Need advance planning
• More family support needed
• New research emerging at rapid rate
26. Poll
• Do you work with or know someone who has LBD?
• Yes
• No
27. Quality of Life Matters
• Comprehensive care of LBD symptoms improves quality of
life and reduces caregiver burden
• Coordinate treatment with patient’s other doctors to avoid
exacerbating symptoms
• Consider referrals to Physical Therapist, Occupational
Therapist and Speech Therapist
28. Caregiver burden
• Treat the primary caregiver as a second patient
• Burden is associated with cognitive, behavioral
or affective symptoms
• Especially disturbances in mood and sleep
• Caregivers should expect crises, especially
trips to the emergency room
29. Poll – open ended question
• Name some of the signs of caregiver burnout
Please use your Questions tab to enter such signs
(separated by commas)
31. Caregiving Tips to
Share
• Focus more on the individual than the disorder
• Maintain a sense of humor
• Limit noise and distractions
• Simplify questions and expectations
• Keep a regular routine
• Address underlying emotions instead of behavior.
• Stay flexible to fluctuating symptoms
• Don’t accept sudden changes as a “normal” progression
32. Poll – open ended question
• What would you do if you suspect a client has
undiagnosed LBD or is possibly misdiagnosed
with another disorder?
33. Help Relieve Caregiver
Burden
• If you or the family suspects LBD – urge a second opinion
at a specialty clinic
• Encourage learning about LBD and talking with other
caregivers
• LBD is likely to overstress and burden families.
• Encourage them to accept help
• Remind caregivers their well-being is equal to patient well-being
• Recommend community-based services and resources
• Watch for grieving
35. Download free diagnostic
and comprehensive
symptom checklists from
LBDA.org
Order print copies of this 40
page booklet from NIA’s
Alzheimer’s Disease Education
and Referral Center
Educational Resources
36. Stay Informed with LBDA
• Visit our homepage, www.lbda.org and click this
image:
• Or visit: http://www.lbda.org/content/sign-lewy-body-
digest-0
Editor's Notes
DLB is responsible for 10-20 percent of all dementias, approximately 1.5 million Americans.
May coexist in the presence of other dementias, e.g. vascular or AZD
Prevalence increases with age – mean age at presentation is 75, slightly more men than women affected
This presentation should make you more aware of some of the unique features of DLB. Of particular importance are issues of prognosis and treatment.
This diagnosis is very difficult to make and often confused with AZD early in its course
The longer the patient is under observation and the more “eyes on the patient” to gather information, the more accurate and helpful we can be.
Round eosinophilic intra-cytoplasmic inclusion bodies
Specific stains can be used to detect the deranged protein, alpha synuclein
Can be found in brainstem areas as well as cortical areas and hippocampus
Amyloid plaques similar to AZD can also be seen, but are not as numerous and AZD hallmark of neuro-fibrillary tangles are rare or non-existant
Lewy Body Disease is a spectrum disorder.
Dementia, MSA, Down Syndrome, and Parkinson’s all share the findings of neuronal destruction and Lewy body formation.
Correct answers are memory loss, interference with function, and 2 or more cognitive areas involved to achieve the diagnosis under DSM 5 criteria. Also, absence of delirium and not explained by another mental disorder such as depression
This case scenario probably indicates he has dementia. Agism may attribute some symptoms to “just getting older”, but these findings are more substantial than normal aging.
New DSM5 also requires no evidence of delirium and not explained by another mental disorder, e.g. depression
Lewy Body is suggested by symptoms as follows. A hallmark of DLB is the appearance early on of delusions and hallucinations which typically do not occur until late in AZD.
Response to medications is also a marker for DLB.
Here are the remarkable symptoms and let’s take a closer look at a few of them.
Difficulty appears when there is a step approach to tasks, e.g. making a shopping list, going to the store, finding the items and checking out, then following a recipe. Visuospatial tasks are those that require eye-hand coordination such as copying a drawing or tracing a path with your finger
Wake-sleep cycles are abnormal
Can do a task one day and not the next
“the baby” and “the phantom border” are two common delusions
Hallucinations are sometimes comical to others, but seriously taken by the patient
Combined with visuospatial dysfunction, this problem can make it hard to feed oneself. Can’t button buttons. Patient appears lethargic and slowed down. Extreme fall risk.
Constipation, lacrimation, salivation, urinary incontinence or bladder paralysis can occur. Of particular concern is hypotension which when combined with motor dysfunction, makes falling a certainty.
A diagnosis of Lewy Body dementia is made by carefully observing all the patients problems and tying the findings together.
Key is continuity of care and observance over time span; with fluctuations of good days and bad, may never see it all come together at once such as with a single office visit.
Keeping a symptom diary will help everyone involved.
Share the same ICD code as a spectrum disorder. Are PD and DLB the same? Arbitrary taxonomy would say so.
Especially analgesics, psychotropics, sedative hypnotics, and anticholinergics. Haldol is the most pronounced of these.
This is an approach to understanding and managing behavioral disturbances of which there will be many. Always need to rule out physical disease such as infection, silent MI, etc. Systematically assess, then try reducing number or dose of some of the medications. Look for new things added to the regimen by someone else or OTC. If control needed, avoid long-acting benzodiazepines and haldol.
Neuroleptic, malignant hyperthermia syndrome
Because LBD wasn’t clinical defined until 1996, research is lagging behind diseases like Alzheimer’s and Parkinson’s.
While there isn’t data available yet on racial and socioeconomic disparities in DLB, it may be useful to look at other Lewy body disorders like Parkinson’s disease for clues.
Possible causes of disparities in PD: Patient attitudes on when to seek treatment at specialized center, problems in diagnosis, access to care, physician referrals
This is the same question we asked at the start of this section of the presentation. Now having heard the symptoms, let’s ask it again. Usually an “AH-HAH” moment occurs here.
LBD is considered a very treatable dementia, as many of its symptoms CAN be ameliorated to some degree with treatment. So comprehensive treatment of all of LBD symptoms is important, as is a focus on palliative care. Managing symptoms like insomnia and constipation can improve the quality of life for both the person with LBD and their primary caregiver.
In addition to medications, non-pharmacological interventions are very important to quality of life.
Physical therapists can help with movement problems through cardiovascular, strengthening, and flexibility exercises, as well as gait training and general physical fitness programs.
Speech therapists may help with low voice volume and voice projection, poor speaking ability, and swallowing difficulties.
Occupational therapists help identify ways to more easily carry out everyday activities, such as eating and bathing, to promote independence.
Music or expressive arts therapists may provide meaningful activities that can reduce anxiety and improve well-being.
Mental health counselors can help people with LBD and their families learn how to manage difficult emotions and behaviors and plan for the future.
Something that many people don’t appreciate is how heavily LBD can impact the primary caregiver.
It’s known that Alzheimer’s caregivers are prone to isolation and depression, have a higher risk of medical illnesses and feelings of guilt. LBDA did a survey of 962 LBD caregivers to understand how the disease affects them
LBD caregivers report medium to high levels of burden
¾’s fear of the future for their loved one
Over half feel stress between caring for their loved one and their personal responsibilities
And half feel uncertainty about what to do as a caregiver
40% report feeling very isolated because nobody knows about LBD
¼ feel that no one understood what they are going through
Spouses reported total greater burden than nonspouses, which is understandable. They are older and more likely to live alone with the person with LBD.
Caregiver burden in LBD is associated with the presence of any cognitive, behavioral or affective symptom. Strongest associations in total caregiver burden were patient disturbances in mood and sleep
Interestingly, when we asked them “Have you had to deal with a crisis situation with the person with LBD in the past year, 64% said yes.
¾ of those who had a crisis included a trip to the emergency room
Other emergencies required EMS or law enforcement
Only 12% required inpatient psychiatric care and another 5% sought help from outpatient mental health services
LBD creates a very challenging set of caregiving demands from early in the disease and it can burn caregivers out early due to its unpredictability. But beyond that, the low public awareness of LBD brings its own emotional toll on families, who have to explain what LBD is to every person they meet, including many of their healthcare providers.
Look for warning signs
Withdrawal from family and friends
Feeling blue or increasingly sad
Changes in sleep patterns
Changes in appetite and/or weight
Getting sick more often
Emotional and physical exhaustion
Increased irritability
While the subjective burden they experience is high, their use of community resources is rather low. 38% reported they received no help at all and only 30% were satisfied with the help they were getting.
Less than half used adult day programs, transportation or meal services. Only 29% used paid care in the home and 21% used adult day services. Less than a 1/3rd attend support groups and only
A new study by Steve Zarit and colleagues suggests that dementia caregivers who regular use adult day care services at least twice a week actually see an increase in a beneficial stress hormone.
This hormone is known to be protective against the physiological damaging effects of stressor exposure and may reduce risks of illness.
Using adult day services may help reduce depletion of this beneficial stress hormone (DHEA-S) and allow the body to mount a protective and restorative response to the physiological demands of caregiving.
Caregiving is more than just the physical care of a person with LBD. It’s good to help them find the best quality of life possible.
Stay focused on them as an individual with emotional and spiritual needs, not just medical needs.
Remember to keep your sense of humor and understand that there are going to be limitations that have to be accepted.
Because people with LBD have a reduced level of attention and alertness, keep the stimulation low to moderate. It will help them not get exhausted from the stimuli.
Take instructions one step at a time. As the disease progresses, offer them a choice of 2 things and then later, simple yes or no questions.
Keep their daily routine relatively stable. Their memory may be relatively good, compared to a person with Alzheimer’s. Knowing what to expect can help to reduce anxiety and resistance to care.
Delusions and hallucinations are common in LBD, so listen to what they are saying and respond to the emotions they are expressing. You can provide a lot of emotional comfort without having to tell them they are wrong or having a hallucination. Don’t forget to try redirecting them to other topics or activities as well.
LBD is never the same two days in a row. Flexibility is the caregiver’s best friend.
Any sudden changes are likely not progression of the disease, but signs of an illness, pain or exhaustion.
LBD is the most misdiagnosed form of dementia. If you or a family suspect LBD, it’s important to seek a second opinion. LBD expertise can often be found at dementia clinics at university hospitals.
Encourage family caregivers to become knowledgeable about LBD symptoms and treatments. They are often the front line protection between the person with LBD and traditional antipsychotics, especially in a hospital setting.
Tell LBD families they can connect with others affected by LBD through support groups or online communities. Because LBD is so highly under-diagnosed, they may not personally know anyone else who has been touched by LBD. They find a tremendous amount of solace and support when they realize they are not alone.
Remember that LBD is a heavy load for family caregivers. Caregivers should be viewed as your second patient and should be screened for caregiver burnout. They need someone else to help them objectively look at their options. I’ll say this from personal experience, as my father had LBD. Many times caregivers think there is only one good caregiving choice, when the truth is that there are several alternatives that we simply refuse to consider for our own personal reasons. But when we get desperate, those alternatives start to look pretty good. It bears saying that if a caregiver is so exhausted that they are sick, depressed, or, and it’s sad to say, but it does happen, suicidal, they cannot do anything for the person they love and are providing care for. Use these tips to help them find ways to balance their caregiving responsibilities with their own physical, emotional and spiritual needs.
Help is available from the Lewy Body Dementia Association.
Our Family Services are designed to help alleviate those feelings of isolation, by putting caregivers directly in touch with other caregivers. Many of our volunteers were former LBD caregivers, so they really understand.
We have a many educational resources on our website, but I’d like to highlight two of our newest ones.
The Diagnostic Symptoms Checklist is a free resource that can be downloaded and printed by families and professionals. It’s a list of key LBD symptoms that are part of the diagnostic process. There are lots of other symptoms, but they are more supportive and are not diagnostic in and of themselves. We also created a comprehensive symptom checklist to make it easier to identify, report and hopefully treat symptoms related to LBD.
This new booklet from the National Institute on Aging was a collaboration between LBDA, the University of California, San Diego, and the National Institutes of Health. You can read the booklet online at LBDA’s website. Print copies can be ordered for free from NIA’s the Alzheimer’s Disease Education and Referral Center (ADEAR).
We encourage you to learn more about LBD and to stay up to date on the latest clinical and scientific news by subscribing to the LBDA’s e-newsletter, the Lewy Body Digest.
Click on this graphic on our homepage or visit the URL listed here.